Lynda G Balneaves, Abeer A Alraja, Genevieve Thompson, Jamie L Penner, Philip St John, Daniella Scerbo, Joanne van Dyck
Cannabis use in a Canadian long-term care facility: a case study
BMC geriatrics
global use certain classical psychedelics increased recent years little known spectrum toxicity within australia aim describe calls new south wales poisons information centre relating exposures classical psychedelics including lysergic acid diethylamide psilocybin nndimethyltryptamine ayahuasca mescaline ibogaine retrospective observational study calls new south wales poisons information centre january 2014 december 2022 identified exposures classical psychedelics within new south wales poisons information centre database measured annual number exposures source call hospital health care worker member public coingested substances clinical features advice given 737 calls related relevant psychedelic exposures 352 478 per cent lysergic acid diethylamide 347 470 per cent psilocybin 28 38 per cent nndimethyltryptamine 4 05 per cent ayahuasca 4 05 per cent mescaline 2 03 per cent ibogaine cases predominantly male 772 per cent aged 20 74 years 656 per cent psychedelic calls doubled 45 2014 105 2022 625 85 per cent calls either referred hospital coingestion psychedelics another substance occurred 249 338 per cent calls frequent clinical features related single substance psychedelic exposures hallucinations 276 per cent gastrointestinal symptoms 217 per cent tachycardia 181 per cent seizures occurred 29 per cent single substance psychedelic exposures increasing incidence psychedelic exposure calls including reporting significant toxicity likely reflects increasing community use may part driven increasing interest psychedelic assisted psychotherapy trials subsequently increasing public awareness relatively high poisoning severity contrasts safety within clinical trials psychedelic assisted psychotherapy may relate uncontrolled nature community use mitigated within clinical trial environments education safe use may useful